- Home
- FHN vs EXAS Comparison
FHN vs EXAS Comparison
Compare FHN & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- EXAS
- Stock Information
- Founded
- FHN 1864
- EXAS 1995
- Country
- FHN United States
- EXAS United States
- Employees
- FHN N/A
- EXAS N/A
- Industry
- FHN Major Banks
- EXAS Medical Specialities
- Sector
- FHN Finance
- EXAS Health Care
- Exchange
- FHN Nasdaq
- EXAS Nasdaq
- Market Cap
- FHN 11.0B
- EXAS 10.2B
- IPO Year
- FHN N/A
- EXAS N/A
- Fundamental
- Price
- FHN $22.26
- EXAS $52.94
- Analyst Decision
- FHN Buy
- EXAS Strong Buy
- Analyst Count
- FHN 17
- EXAS 22
- Target Price
- FHN $23.32
- EXAS $67.38
- AVG Volume (30 Days)
- FHN 11.2M
- EXAS 2.8M
- Earning Date
- FHN 10-15-2025
- EXAS 11-04-2025
- Dividend Yield
- FHN 2.69%
- EXAS N/A
- EPS Growth
- FHN 28.04
- EXAS N/A
- EPS
- FHN 1.55
- EXAS N/A
- Revenue
- FHN $3,083,000,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- FHN $10.95
- EXAS $16.68
- Revenue Next Year
- FHN $3.68
- EXAS $12.08
- P/E Ratio
- FHN $14.39
- EXAS N/A
- Revenue Growth
- FHN 4.62
- EXAS 12.55
- 52 Week Low
- FHN $14.83
- EXAS $38.81
- 52 Week High
- FHN $23.08
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- FHN 49.10
- EXAS 59.35
- Support Level
- FHN $21.99
- EXAS $46.30
- Resistance Level
- FHN $23.08
- EXAS $56.52
- Average True Range (ATR)
- FHN 0.45
- EXAS 1.65
- MACD
- FHN -0.05
- EXAS 0.47
- Stochastic Oscillator
- FHN 28.07
- EXAS 65.44
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.